METHODS and RESULTS
Following a multidisciplinary diagnosis and treatment, it was determined
that the current effectiveness of sunitinib in treating GIST metastasis
was unsatisfactory. Therefore, a debulking surgery followed by targeted
therapy was recommended to maximize the patient’s lifespan. The
postoperative pathology reports indicated a high-risk GIST (Figure 3B),
with immunohistochemical analysis showing CD117 (++++), CD34 (+), SMA
(++++), Dog1 (++++), Desmin (-), S-100 (-), ki-67 (25%+), and SDHB
(++++). Genetic testing revealed c-KIT exon 11 mutation sites. The
patient received postoperative treatment with a conventional dose of the
third-generation TKI, regorafenib. Regular follow-up examinations
conducted over a span of nine months until December 2022 revealed no
significant progression of metastases.